OBJECTIVES: In 2015, the Committee on Medicinal Products of the 37 Paris Publics Hospitals (AP-HP, the largest hospital group in Europe – €1 billion of drug expenditures and 7 million patients hospitalized annually) authorized the tender between two infliximab biosimilars (BIOSIM-INFLIX) and their originator (ORIGIN-INFLIX) only for naive-patients, as the current French law did not allow the switch from originator biologics to biosimilars for pretreated-patients. A BIOSIM-INFLIX won the tender and the ORIGIN-INFLIX has been listed in the AP-HP hospital drug formulary (HDF) since September 2015 for pretreated-patients. This study analyzes the spread of BIOSIM-INFLIX and of ORIGIN-INFLIX in AP-HP one year after the tender. METHODS: Infliximab consumption and expenses data were analyzed over the 2015-2016 period to retrospectively assessed BIOSIM-INFLIX and ORIGIN-INFLIX market shares within the 37 hospitals. RESULTS: Infliximab expenses in AP-HP in 2016 were down 13.5% compared to 2015 (€34.8 vs. €39.5 million), while infliximab consumption in volume globally increased by 8.8%. The rise in infliximab consumption was offset by a negative price effect due to the competition of BIOSIM-INFLIX (-45% and -34.5% price discounts for BIOSIM-INFLIX and for ORIGIN-INFLIX respectively). In 2016, infliximab products were used in 20 AP-HP hospitals and the average of BIOSIM-INFLIX uptakes in volume reached 28.4% in AP-HP (vs. 11.5% in France). However, BIOSIM-INFLIX uptakes are heterogeneous among AP-HP hospitals: [80%-90%] (n=2), [60%-40%] (n=2), [30%-10%] (n=9), <10% (n=7). The 3 pediatric AP-HP hospitals decided to list only the ORIGIN-INFLIX in their local HDF. No correlation was found between hospitals’ infliximab consumption and BIOSIM-INFLIX uptakes. CONCLUSIONS: Until a new law governing the substitution for patients receiving biologics in France develops, the BIOSIM-INFLIX uptakes today depend on the will of hospital physicians to switch from biosimilars to originators. The therapeutic indications in which BIOSIM-INFLIX and ORIGIN-INFLIX are used and the naive/pretreated status of patients must now be explored.